← Back to Search

Early Treatment arm for Temozolomide (IWOT Trial)

Phase 3
Waitlist Available
Led By Martin Van den Bent
Research Sponsored by European Organisation for Research and Treatment of Cancer - EORTC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the iwot seizure control composite score index can be completed up to 4 weeks before or after the planned assessment. a time window of 8 weeks is therefore available for each assessment. assessed up to 11.5 years after fpi
Awards & highlights
Pivotal Trial
No Placebo-Only Group

Summary

This trial will test whether early treatment can help patients with IDH-mutated astrocytomas, and if it's worth the possible side-effects.

Eligible Conditions
  • Temozolomide
  • Brain Tumor
  • Clinical Trials
  • Watchful Waiting

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the iwot seizure control composite score index can be completed up to 4 weeks before or after the planned assessment. a time window of 8 weeks is therefore available for each assessment. assessed up to 11.5 years after fpi
This trial's timeline: 3 weeks for screening, Varies for treatment, and the iwot seizure control composite score index can be completed up to 4 weeks before or after the planned assessment. a time window of 8 weeks is therefore available for each assessment. assessed up to 11.5 years after fpi for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
HRQoL related to seizures
Safety profile: CTCAE
Seizure activity
+1 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Early Treatment armExperimental Treatment2 Interventions
Radiotherapy + Temozolomide
Group II: Active surveillance armActive Control3 Interventions
Treatment as per local practice
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Temozolomide
2010
Completed Phase 3
~1880
Radiotherapy
2017
Completed Phase 3
~2610

Find a Location

Who is running the clinical trial?

European Organisation for Research and Treatment of Cancer - EORTCLead Sponsor
414 Previous Clinical Trials
165,662 Total Patients Enrolled
Cooperative Trials Group for Neuro-Oncology (COGNO)UNKNOWN
Martin Van den BentPrincipal InvestigatorEORTC Study Coordinator
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top